Product Information
HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET is a generic product labeled by Amneal Pharmaceuticals of New York LLC, priced at $0.1361 per EA under NDC 53746010905. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Aug 25, 2006. Its Orange Book therapeutic-equivalence code is AA.
Strength
325; 5 mg/1; mg/1
Manufacturer
Amneal Pharmaceuticals of New York LLCNDC
53746010905
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; HYDROCODONE BITARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA040736FDA Approved
8/25/2006
TE Code
AA
On Market Since
1/18/2010
Pharmacological Classes
Price Statistics
The NADAC for HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1361 per EA |
|---|---|
| All-time high | $0.1957 (May 13, 2015) |
| All-time low | $0.0764 (Nov 20, 2019) |
| 52-week high | $0.1388 |
| 52-week low | $0.1273 |
| Median price | $0.1181 |
| Average price | $0.1182 |
| Largest weekly change | +35.0% (Dec 17, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 22% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Amneal Pharmaceuticals of New York LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Hydrocodone Bitartrate and Acetaminophen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET, manufactured by Amneal Pharmaceuticals of New York LLC, is $0.1361 per EA (NDC 53746010905), effective Sep 30, 2026.
How has the price of HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET changed over time?
Over the history we have for it, the NADAC for HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET has held within roughly two percent of its current level. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET?
Since Nov 28, 2013, the NADAC for HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET has ranged from a low of $0.0764 (Nov 20, 2019) to a high of $0.1957 (May 13, 2015), with a median of $0.1181 per EA.
Are there cheaper alternatives to HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET, is $0.1066 per EA — about 22% below HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET.
Who manufactures HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET?
HYDROCODONE-ACETAMINOPHEN 5-325 MG TABLET (NDC 53746010905) is labeled by Amneal Pharmaceuticals of New York LLC, and CMS classifies it as a generic product.